World Economy and Management research
Cure8 research brief
Why This Matters
This links a commonly used anti‑TNF drug (infliximab) to changes in molecules (MMP‑9, MMP‑2) involved in tissue remodeling and suggests a measurable EV‑RAGE–NLRP3 pathway that could help explain or track how treatment affects intestinal injury in Crohn’s disease.
Who Should Pay Attention
Clinicians treating Crohn’s patients with biologics, researchers studying IBD immune mechanisms or biomarkers, and patients on or considering anti‑TNF therapy who follow mechanistic or biomarker research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study of 42 patients with active Crohn’s disease receiving infliximab induction found that infliximab reduced serum MMP-9 (especially in clinical responders) and modestly increased MMP-2.
The investigators measured circulating extracellular vesicle (EV) RAGE content, NLRP3 inflammasome activation in PBMCs, and serum IL‑1β; patient-derived EVs activated NLRP3 and induced MMP-9 release in healthy PBMCs, effects reduced by a RAGE-blocking antibody or the NLRP3 inhibitor MCC950.
The authors conclude that infliximab’s effect on MMP-9 may be mediated partly by lowering EV-associated RAGE and suppressing NLRP3-driven MMP-9 production, proposing the EV‑RAGE–NLRP3 axis as a potential biomarker or mechanism related to anti‑TNF effects on matrix remodeling.
This brief is grounded in the article abstract provided (structured content depth: abstract). It summarizes reported methods and findings but does not substitute for the full paper or peer review; the full text and independent replication would be needed to apply these findings clinically.
Keep In Mind
The source text available is an abstract-level article report. Findings are from a relatively small single study and describe mechanistic associations and ex vivo experiments; they do not by themselves change clinical management. Larger studies and clinical validation would be needed before using EV‑RAGE or MMP levels as treatment decisions tools.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationWorld Economy and Management research
AuthorsDan Long, 唐峰波, Yong He +2 more
InstitutionUniversity of South China
Study typeArticle
Indexed viaOpenAlex
Source typeResearch paper
PublishedNov 1, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Longitudinal visceral adipose heterogeneity supports digital health stratification of infliximab response loss in Crohn disease
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
Circulating microRNAs as biomarkers of disease activity and treatment response in Crohn’s disease patients receiving infliximab or vedolizumab: a longitudinal cohort study
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
Clinical study on the screening of biomarkers for Crohn's disease based on blood metabolomics.
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...